Evidence map›Paper›PMID 24252813›Full record

ArticleThe Journal of antibiotics2014

Venturicidin C, a new 20-membered macrolide produced by Streptomyces sp. TS-2-2.

Khaled A Shaaban, Shanteri Singh, Sherif I Elshahawi, Xiachang Wang, Larissa V Ponomareva, Manjula Sunkara, Gregory C Copley, James C Hower, Andrew J Morris, Madan K Kharel and 1 more

Abstract read
In one paragraph

Article in The Journal of antibiotics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Review
  2. Article
  3. Antibiotics (Basel, Switzerland) · 2023
    Article
  4. Macrolides fromMicroorganisms · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Leveraging ecological theory to guide natural product discovery.Journal of industrial microbiology & biotechnology · 2016
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Khaled A ShaabanCollege of Pharmacy, Center for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY, USA.
Shanteri SinghCollege of Pharmacy, Center for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY, USA.
Sherif I ElshahawiCollege of Pharmacy, Center for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY, USA.
Xiachang WangCollege of Pharmacy, Center for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY, USA.
Larissa V PonomarevaCollege of Pharmacy, Center for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY, USA.
Manjula SunkaraDivision of Cardiovascular Medicine, University of Kentucky, Lexington, KY, USA.
Gregory C CopleyCenter for Applied Energy Research, University of Kentucky, Lexington, KY, USA.
James C HowerCenter for Applied Energy Research, University of Kentucky, Lexington, KY, USA.
Andrew J MorrisDivision of Cardiovascular Medicine, University of Kentucky, Lexington, KY, USA.
Madan K KharelCollege of Pharmacy, Center for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY, USA.
Jon S ThorsonCollege of Pharmacy, Center for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY, USA.

Funding

The role of IKKß in linking obesity to adipose tissue inflammation and adipogeneP20GM103527 · NIGMS · UNIVERSITY OF KENTUCKY · PI REN, HONGMEI · 2012 to 2017
$13.7M
Kentucky Center for Clinical and Translational ScienceUL1TR000117 · NCATS · UNIVERSITY OF KENTUCKY · PI KERN, PHILIP A · 2012 to 2015
$13.3M
Thermo/Finnigan TSQ AM Triple Stage Quadrupole Mass SpectrometerS10RR024598 · NCRR · UNIVERSITY OF KENTUCKY · PI MORRIS, ANDREW J · 2008 to 2008
$493k
Advion Triversa Nanomate/ABSciex Nanospray III Ion Source for Targeted LipidomicsS10RR026884 · NCRR · UNIVERSITY OF KENTUCKY · PI MORRIS, ANDREW J · 2011 to 2011
$106k
NCATS NIH HHS UL1 TR000117NCATS NIH HHS UL1TR000117NCRR NIH HHS S10 RR024598NCRR NIH HHS S10 RR026884NIGMS NIH HHS P20 GM103527
6 · The paper itself

Abstract

Venturicidin C (1), a new 20-membered macrolide along with the known venturicidins A (2) and B (3) were isolated from the crude extract of the Appalachian bacterial strain Streptomyces sp. TS-2-2. Additionally, nine other known compounds namely nocardamine, dehydroxynocardamine, desmethylenylnocardamine, ferrioxamine E, adenosine, riboflavin, cyclo(D)-trans-4-OH-Pro-(D)-Phe, cyclo(D)-Pro-(D)-Phe and N-(2-phenylethyl)-acetamide were also isolated and identified. The structure of the new macrolide 1 was elucidated by the cumulative analyses of NMR spectroscopy and HR-MS data. Complete NMR assignments for the known venturicidins A (2) and B (3) are also provided, for the first time, in this report. Venturicidins A-C did not inhibit the proliferation of A549 lung cancer cell line but all displayed potent antifungal activity.

Indexed as

Antifungal AgentsCell Line, TumorHumansLung NeoplasmsMacrolidesMagnetic Resonance SpectroscopyMass SpectrometryPeptides, CyclicStreptomycesAntifungal AgentsMacrolidesPeptides, Cyclicventuramide Aventuramide Bventuricidin C

Identifiers

PMID24252813
PMCPMC3969387

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.